The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Hematology"
DOI: 10.1007/s00277-017-3161-0
Abstract: For decades, researchers have looked into the pathophysiology of acute myeloid leukemia (AML). With the advances in molecular techniques, the two-hit hypothesis was replaced by a multi-hit model, which also emphasizes the importance of aberrant… read more here.
Keywords: idh1 idh2; myeloid leukemia; idh2; acute myeloid ... See more keywords
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-017-0418-6
Abstract: Purpose of ReviewOver the past decade, the pathogenic role of mutations in isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with AML, has been defined, allowing for the development of specific therapeutic… read more here.
Keywords: mutations acute; idh1 idh2; idh2 mutations; myeloid leukemia ... See more keywords
Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Medical Oncology"
DOI: 10.1007/s12032-018-1229-x
Abstract: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert isocitrate to α-ketoglutarate. Somatic point mutations in IDH1/2 confer a gain-of-function in cancer cells, resulting in overproduction of an oncometabolite, 2-hydroxyglutarate… read more here.
Keywords: esophageal squamous; idh1 idh2; isocitrate dehydrogenase; idh2 mutations ... See more keywords
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
Sign Up to like & getrecommendations! Published in 2021 at "Blood Cancer Journal"
DOI: 10.1038/s41408-021-00497-1
Abstract: Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy; approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2. These recurrent mutations in key metabolic enzymes lead to the… read more here.
Keywords: idh1 idh2; myeloid; myeloid leukemia; acute myeloid ... See more keywords
Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of laboratory hematology"
DOI: 10.1111/ijlh.13648
Abstract: OBJECTIVE Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) frequently emerge in acute myeloid leukemia (AML), but the clinical features and molecular characteristics of IDH mutational status and other coexisting mutations have… read more here.
Keywords: mutated patients; idh1 idh2; myeloid leukemia; acute myeloid ... See more keywords
Abstract 740: Rapid detection of IDH1/2 mutations using RNaseH2 dependent, multiplex quantitative PCR Assays
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-740
Abstract: Isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are enzymes that normally catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate during glucose metabolism. Heterozygous mutations in the IDH1 and IDH2 genes have been identified in a… read more here.
Keywords: idh1 idh2; quantitative pcr; idh1; detection idh1 ... See more keywords
Combinational analysis of IDH1/IDH2 mutations, 1p/19q deletions and MGMT promoter methylation for molecular testing of glioma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e13152
Abstract: e13152 Background: Mutations in IDH1 and IDH2, co-deletion of 1p and 19q, and the hyper methylation of the MGMT promoter are the most reported genetic alterations in glioma tumors. Therefore, we designed a study to… read more here.
Keywords: methylation; mgmt promoter; idh1 idh2; idh2 mutations ... See more keywords
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.639387
Abstract: Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the… read more here.
Keywords: idh1 idh2; myeloid leukemia; idh2 inhibition; acute myeloid ... See more keywords
Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review
Sign Up to like & getrecommendations! Published in 2022 at "Current Issues in Molecular Biology"
DOI: 10.3390/cimb44100348
Abstract: Both IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2) mutations play a vital role in the development of gliomas through disruption of normal cellular metabolic processes. Here we describe a case of a patient… read more here.
Keywords: idh2 mutations; mutations survival; systematic review; idh1 idh2 ... See more keywords
Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Genes"
DOI: 10.3390/genes13112075
Abstract: Molecular biomarkers, such as IDH1/IDH2 mutations and 1p19q co-deletion, are included in the histopathological and clinical criteria currently used to diagnose and classify gliomas. IDH1/IDH2 mutation is a common feature of gliomas and is associated… read more here.
Keywords: methylation; signature; dna methylation; idh1 idh2 ... See more keywords